MTOR and triple-negative breast carcinoma: Accordingly, it has been reported that patients with advanced MBC treated with an mTOR-based systemic therapy regimen (temsirolimus or everolimus with liposomal doxorubicin and bevacizumab) had better long-term outcomes compared with patients with non-metaplastic triple-negative breast cancer treated with the same regimen, suggesting that metaplastic histology may predict benefits from agents targeting the PI3K/AKT/mTOR pathway.